BBIO · BridgeBio Pharma, Inc.
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $579.96M | $502.08M | $221.9M | $9.3M | $77.65M | $69.72M | $8.25M | $40.56M | |
| $28.26M | $20.96M | $3.88M | $2.45M | — | $2.74M | — | — | |
| $551.7M | $481.11M | $218.02M | $6.86M | — | $66.98M | — | — | |
| — | 95.82% | 98.25% | 73.71% | — | 96.08% | — | — | |
| $467.16M | $451.95M | $506.46M | $455.71M | $399.46M | $451.02M | $337.05M | $209.95M | |
| $156.83M | — | — | — | — | — | $145.68M | $94.35M | |
| $588.76M | $531.23M | $288.93M | $150.59M | $143.19M | $192.21M | — | — | |
| $2.8M | $2.7M | $2.4M | $2.4M | $2.4M | $2.6M | — | — | |
| — | $5.43M | $6.08M | $6.49M | $6.77M | $5.84M | — | — | |
| — | — | $15.61M | $7.93M | $43.77M | — | — | — | |
| $548.21M | — | — | — | — | — | $482.73M | $306.8M | |
| $1.1B | $1.03B | $814.88M | $616.67M | $589.85M | $646.35M | — | — | |
| -$525M | -$523.41M | -$592.97M | -$607.37M | -$512.2M | -$576.63M | -$474.48M | -$266.24M | |
| — | -104.25% | -267.22% | -6528.75% | -659.65% | -827.12% | -5751.99% | -656.41% | |
| — | -$517.98M | -$586.9M | -$600.88M | -$505.43M | -$570.79M | — | — | |
| $47.92M | $53.1M | $99.29M | $81.29M | $80.44M | $46.78M | $36.66M | $8.77M | |
| $20.72M | $19.85M | $17.25M | $18.04M | $7.54M | $1.13M | $4.02M | $8.92M | |
| -$204.46M | -$209.09M | $50.78M | -$45.88M | $27.55M | -$9.82M | -$31.01M | -$22.35M | |
| -$75.34M | -$72.61M | -$31.18M | — | — | -$20.87M | -$20.87M | -$20.87M | |
| — | -$732.5M | -$542.19M | — | — | — | $505.49M | $288.59M | |
| — | $435K | $1.15M | — | — | — | — | — | |
| -$729.89M | -$732.94M | -$543.35M | -$653.25M | -$484.65M | -$586.45M | -$505.49M | -$288.59M | |
| — | -145.98% | -244.86% | -7021.94% | -624.17% | -841.2% | -6127.87% | -711.5% | |
| -$8.33M | -$8.01M | -$7.59M | -$10.05M | -$3.47M | -$23.92M | -$56.76M | -$28M | |
| -$721.55M | -$724.93M | -$535.76M | -$643.2M | -$481.18M | -$562.54M | -$448.72M | -$260.59M | |
| -$721.56M | -$724.93M | -$535.79M | -$642.84M | -$481.38M | -$562.86M | -$448.79M | -$260.33M | |
| USD/shares | — | -$3.78 | -$2.88 | -$3.95 | -$3.26 | — | — | — |
| USD/shares | — | -$3.78 | -$2.88 | -$3.95 | -$3.26 | — | — | — |
| shares | — | 191.53M | 186.08M | 162.79M | 147.47M | 144.36M | 118M | 105.1M |
| shares | — | 191.53M | 186.08M | 162.79M | 147.47M | 144.36M | 118M | 105.1M |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2019–FY2025: $323.28M in buybacks, $997K in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 118 similar-size Biotechnology companies (of 521 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $502,076,000 | $221,902,000 | $9,303,000 | — |
| Reportable Segment Aggregation Before Other Operating Segment | — | — | — | $77,648,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Product | $362,368,000 | $2,884,000 | $0 | $1,554,000 | $3,793,000 | $0 | — |
| License And Service | $128,322,000 | $218,849,000 | $9,303,000 | $76,094,000 | $65,923,000 | $8,249,000 | — |
| Royalty | $11,386,000 | $169,000 | $0 | — | — | — | — |
| License | — | — | — | — | — | — | $40,560,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | -$523,411,000 | -$592,973,000 | -$607,370,000 | — |
| Reportable Segment Aggregation Before Other Operating Segment | — | — | — | -$512,202,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | -104.2% | -267.2% | -6528.8% | — |
| Reportable Segment Aggregation Before Other Operating Segment | — | — | — | -659.6% |